These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2858546)

  • 1. The effect of formulation on oesophageal transit.
    Channer KS; Virjee JP
    J Pharm Pharmacol; 1985 Feb; 37(2):126-9. PubMed ID: 2858546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of size and shape of tablets on their esophageal transit.
    Channer KS; Virjee JP
    J Clin Pharmacol; 1986 Feb; 26(2):141-6. PubMed ID: 3950057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oesophageal transit of six commonly used tablets and capsules.
    Hey H; Jørgensen F; Sørensen K; Hasselbalch H; Wamberg T
    Br Med J (Clin Res Ed); 1982 Dec; 285(6356):1717-9. PubMed ID: 6816343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of left atrial size on the oesophageal transit of capsules.
    Channer KS; Bell J; Virjee JP
    Br Heart J; 1984 Aug; 52(2):223-7. PubMed ID: 6234911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired oesophageal transit of capsule versus tablet formulations in the elderly.
    Perkins AC; Wilson CG; Blackshaw PE; Vincent RM; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Gut; 1994 Oct; 35(10):1363-7. PubMed ID: 7959187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
    Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
    Perkins AC; Blackshaw PE; Hay PD; Lawes SC; Atherton CT; Dansereau RJ; Wagner LK; Schnell DJ; Spiller RC
    Clin Ther; 2008 May; 30(5):834-44. PubMed ID: 18555931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of delayed esophageal transit on acetaminophen absorption.
    Channer KS; Roberts CJ
    Clin Pharmacol Ther; 1985 Jan; 37(1):72-6. PubMed ID: 3965238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Dansereau RJ; Vincent RM; Wenderoth D; Hathaway S; Li Z; Spiller RC
    Int J Pharm; 2001 Jul; 222(2):295-303. PubMed ID: 11427359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oesophageal function tests: are they of value?
    Channer KS; Virjee JP
    Clin Radiol; 1985 Sep; 36(5):493-6. PubMed ID: 4075719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
    Perkins AC; Wilson CG; Frier M; Blackshaw PE; Juan D; Dansereau RJ; Hathaway S; Li Z; Long P; Spiller RC
    Aliment Pharmacol Ther; 2001 Jan; 15(1):115-21. PubMed ID: 11136284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of hyoscine butylbromide on the swallowing of capsules.
    Channer KS; Wolinski A; Kaye B; Virjee J
    Br J Clin Pharmacol; 1983 May; 15(5):560-3. PubMed ID: 6860531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oesophageal transit of a radionuclide solid bolus in normals.
    Kjellén G; Svedberg JS
    Clin Physiol; 1983 Feb; 3(1):69-74. PubMed ID: 6299643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity.
    Osmanoglou E; Van Der Voort IR; Fach K; Kosch O; Bach D; Hartmann V; Strenzke A; Weitschies W; Wiedenmann B; Trahms L; Mönnikes H
    Neurogastroenterol Motil; 2004 Oct; 16(5):547-56. PubMed ID: 15500511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine absorption after delayed oesophageal capsule transit.
    Channer KS; Roberts CJ
    Br J Clin Pharmacol; 1984 Aug; 18(2):250-3. PubMed ID: 6487466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oesophageal transit of small tablets.
    Robertson CS; Hardy JG
    J Pharm Pharmacol; 1988 Aug; 40(8):595-6. PubMed ID: 2907022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Esophageal transit of 6 common types of tablets and capsules].
    Hey H; Jorgensen F; Sorensen K; Hasselback H; Wanberg T
    Riv Inferm; 1985 Jun; 4(2):82-5. PubMed ID: 3933094
    [No Abstract]   [Full Text] [Related]  

  • 18. Esophageal transit of capsules in clinically normal cats.
    Graham JP; Lipman AH; Newell SM; Roberts GD
    Am J Vet Res; 2000 Jun; 61(6):655-7. PubMed ID: 10850841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients' evaluation of shape, size and colour of solid dosage forms.
    Overgaard AB; Højsted J; Hansen R; Møller-Sonnergaard J; Christrup LL
    Pharm World Sci; 2001 Oct; 23(5):185-8. PubMed ID: 11721676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standardization of clinical criteria required for use of the 12.5 millimeter barium tablet in evaluating esophageal lumenal patency.
    Gallo SH; McClave SA; Makk LJ; Looney SW
    Gastrointest Endosc; 1996 Aug; 44(2):181-4. PubMed ID: 8858325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.